NCT07434544Recruiting
Cardiometabolic Effects of Non-Nutritive Sweeteners (NNS) in Type 1 Diabetes (T1D)
The Cardiometabolic Impact of Non-Nutritive Sweeteners in Young Adults With Type 1 Diabetes
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This project will apply a novel non-nutritive sweetener (NNS) dietary assessment tool with measurement of circulating NNS levels in a pediatric population, allowing correlation of NNS exposure to clinically meaningful cardiometabolic health outcomes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- First submitted
- 27 Jan 2026
- Start date
- 5 Aug 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Medical College of Wisconsin
- Diseases
- Type 1 diabetes
- NCT number
- NCT07434544
What you commit to
- Study type: Interventional
- Planned participants: 20
- From 5 Aug 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Known cardiovascular disease such as hypertension or atherosclerosis, and/or use of an anti-hypertensive medication
- Known renal disease or microalbuminuria, and/or use of angiotensin-converting enzyme (ACE) inhibitor or angiotensin II receptor blockers (ARBs) for microalbuminuria
- Raynaud's phenomenon or other vascular disease
- Any condition that, in the investigator's opinion, may compromise study participation or may confound the interpretation of the study results.
Lab values
- Any disease other than type 1 diabetes that affects glucose, sex steroid, or fat metabolism such as polycystic ovary syndrome or hypercortisolism
- Any medication use that may affect glucose, sex steroid, or fat metabolism such as metformin or glucocorticoids
- Known hyperlipidemia, defined as LDL ≥ 160 mg/dL, and/or use of lipid-lowering medication, such as statin therapy
Other
- Half or full sibling already participating in this study
- Known diabetic retinopathy or neuropathy
- Obesity and/or body habitus that precludes completion of the flow-mediated brachial ultrasound study (generally, BMI \> 40 kg/m2 in adults) - this is at study team's discretion.
- Pregnancy or lactation
Who the study is looking for
- Aged 15-24 years
- Clinical diagnosis of type 1 diabetes, requiring insulin therapy, of ≥ 1 to \< 10 years duration.
- Last available HbA1c ≤ 8.5% (obtained by chart review in Children's Wisconsin Diabetes Clinic patients or verbally by individuals not receiving diabetes care at Children's Wisconsin)
- Current use of an FDA approved automated insulin delivery (AID) system
- Willing to consume a 12 ounce Gatorade G Zero Glacier Cherry drink in less than 10 minutes
- Willing and able to give informed consent or have parent or legal guardian provide informed consent if the subject is \< 18 years of age
Age in the registry: 15 years to 24 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical College of Wisconsin Coordinator of this site? Confirm its status | Milwaukee | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.